Aaron Cowen Suvretta Capital Management
Aaron Cowen is the founder of Suvretta Capital Management, a long/short equity firm with a fundamental research process. The firm invests across sectors with an emphasis on differentiated fundamental views. Cowen’s disclosures are tracked by investors who follow mid-to-large fundamental hedge funds.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Coca-Cola
KO
|
+$58.2M |
| 2 |
Dick's Sporting Goods
DKS
|
+$48.3M |
| 3 |
GE HealthCare
GEHC
|
+$37.1M |
| 4 |
Danaher
DHR
|
+$31.2M |
| 5 |
GE Aerospace
GE
|
+$24M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Insmed
INSM
|
+$95.9M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$92.5M |
| 3 |
Microsoft
MSFT
|
+$35.3M |
| 4 |
Chipotle Mexican Grill
CMG
|
+$27.1M |
| 5 |
United Airlines
UAL
|
+$26.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 48.97% |
| 2 | Technology | 9.89% |
| 3 | Consumer Discretionary | 5.64% |
| 4 | Financials | 4.91% |
| 5 | Communication Services | 4.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Monte Rosa Therapeutics
GLUE
$1.22B
| $15.2M | 0.46% |
3,360,000
+1,796,202
| +115% | +$8.01M |
|
52
Moderna
MRNA
$57.9B
| $14.3M | 0.43% |
517,163
| – | – |
|
53
Kymera Therapeutics
KYMR
$9.96B
| $12M | 0.36% |
+275,000
| New | +$9.47M |
|
54
Rocket Pharmaceuticals
RCKT
$385M
| $10.2M | 0.31% |
4,143,333
+641,333
| +18% | +$3.25M |
|
|
MOLN
55
Molecular Partners
MOLN
$165M
| $8.49M | 0.26% |
2,221,494
| – | – |
|
56
Taysha Gene Therapies
TSHA
$1.98B
| $7.43M | 0.22% |
+3,217,449
| New | +$6.99M |
|
57
ProKidney
PROK
$336M
| $7.31M | 0.22% |
12,341,266
| – | – |
|
|
WHWK
58
Whitehawk Therapeutics
WHWK
$270M
| $6.92M | 0.21% |
3,700,000
| – | – |
|
|
CTNM
59
Contineum Therapeutics
CTNM
$647M
| $6.83M | 0.21% |
1,720,000
| – | – |
|
60
Abbott
ABT
$202B
| $5.51M | 0.17% |
40,520
-18,300
| -31% | -$2.41M |
|
61
InflaRx
IFRX
$309M
| $5.12M | 0.15% |
6,483,910
| – | – |
|
62
Zura Bio
ZURA
$561M
| $5.1M | 0.15% |
4,860,939
| – | – |
|
|
EXAS
63
DELISTED
Exact Sciences
EXAS
| $5M | 0.15% |
94,100
| – | – |
|
64
Sutro Biopharma
STRO
$349M
| $4.63M | 0.14% |
648,832
-97,418
| -13% | -$797K |
|
65
Regeneron Pharmaceuticals
REGN
$85.9B
| $4.53M | 0.14% |
+8,630
| New | +$4.82M |
|
66
Cencora
COR
$60.7B
| $3.74M | 0.11% |
12,488
| – | – |
|
67
Elanco Animal Health
ELAN
$12B
| $3.62M | 0.11% |
253,600
| – | – |
|
|
KZR
68
DELISTED
Kezar Life Sciences
KZR
| $3.28M | 0.1% |
716,759
| – | – |
|
69
Thermo Fisher Scientific
TMO
$233B
| $3.2M | 0.1% |
7,900
| – | – |
|
70
Intuitive Surgical
ISRG
$134B
| $2.83M | 0.09% |
5,200
| – | – |
|
71
DexCom
DXCM
$34.8B
| $2.77M | 0.08% |
31,680
| – | – |
|
72
Stryker
SYK
$126B
| $2.32M | 0.07% |
5,860
| – | – |
|
73
Mettler-Toledo International
MTD
$28B
| $2.31M | 0.07% |
1,964
| – | – |
|
74
Medtronic
MDT
$119B
| $2.18M | 0.07% |
25,060
| – | – |
|
75
Natera
NTRA
$47.9B
| $1.71M | 0.05% |
10,100
| – | – |
|
Similar funds
Aaron Cowen's Q2 2025 Portfolio in Review
As of Q2 2025, Aaron Cowen held 112 positions worth $3.32B, up 23% from $2.69B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Aaron Cowen deployed $387M of net new capital in Q2 2025, opening 12 new positions and adding to 30 existing holdings. Its largest new stake was Dick's Sporting Goods: 260,465 shares worth $51.5M.
By sector, the portfolio is most concentrated in Healthcare at 49% of assets, down from 60% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Insmed, an estimated $95.9M trimmed.
- Aaron Cowen's largest Q2 2025 buy was Dick's Sporting Goods: 260,465 shares worth $51.5M.
- Aaron Cowen added most to Coca-Cola in Q2 2025, an estimated $58.2M increase.
- Aaron Cowen's biggest Q2 2025 reduction was Insmed, cutting an estimated $95.9M.
- Aaron Cowen fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $92.5M.
- Aaron Cowen's ten largest holdings make up 46% of its $3.32B portfolio in Q2 2025.
- Aaron Cowen opened 12 new positions and closed 14 in Q2 2025.
- Aaron Cowen's portfolio value rose 23% quarter-over-quarter to $3.32B.
Based on Suvretta Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.